Dr. Frances Shepherd recognized for her contributions to lung cancer treatment

Dr. Frances Shepherd has led a multi-disciplinary team of cancer specialists that has changed the standard of care for lung cancer patients around the world.

In February 2015, she will once again be recognized for her achievements as she receives the Claude Jacquillat Award from the International Congress on Anti-Cancer treatment. This award is named after the late professor Claude Jacquillat, the founder of the department of Medical Oncology of the Pitie Salpetriere Hospital and an internationally recognized cancer researcher who made major contributions to new drug development. Winners of this award are recognized for outstanding contributions to cancer patient care.

The award recognizes Dr. Shepherd's long-standing international leadership in the development and implementation of innovative therapies in lung cancer, and her leadership in bringing together basic and clinical researchers to build one of the world's foremost groups of translational researchers in lung cancer.

In addition to her contributions in Toronto at Princess Margaret Cancer Centre, Dr. Shepherd chaired the National Cancer Institute of Canada Clinical Trials Group Lung Cancer Committee. In 2006, she was recipient of the coveted O.Harold Warwick prize for her contributions to cancer control in Canada, and in 2007 received the prestigious Scientific Award from the International Association for the Study of Lung Cancer (IASLC) and Order of Ontario. In 2012, the British Thoracic Oncology Group honoured Dr. Shepherd with the International Award for Contributions to Lung Cancer.

Dr. Shepherd has also worked closely with The Princess Margaret Cancer Foundation to raise over $20 million for the cause she has devoted her working life to. With these funds, numerous research chairs have been established to ensure that our leading lung cancer researchers have the funds needed to conduct their promising research.

Dr. Shepherd will be presented with the award during the Presidential Session at the 26th International Congress on Anticancer Treatment to be held from February 3rd to February 5th, 2015.